The treatment of Glioblastoma Xenografts by surfactant conjugated dendritic nanoconjugates

Biomaterials

Volumn 32, Issue 26, 2011, Pages 6213-6225

  Gajbhiye, Virendra ^a   Jain, Narendra K ^a  

^a DR H S GOUR UNIVERSITY   (India)

Author keywords

Animal model; Apolipoprotein; Brain; Dendrimer; Drug delivery

Indexed keywords

ANIMAL MODEL; ANTICANCER ACTIVITIES; ANTICANCER DRUG; APOLIPOPROTEINS; BIODISTRIBUTIONS; BRAIN TUMORS; DOCETAXEL; GLIOBLASTOMA CELLS; GLIOBLASTOMAS; IN-VITRO; IN-VIVO; MEDIAN SURVIVAL; NANOCONJUGATES; POLY(PROPYLENE IMINE); POLYSORBATE 80; TUMOR VOLUMES;

BEARINGS (STRUCTURAL); CELL CULTURE; DENDRIMERS; DISEASES; DRUG DELIVERY; NUCLEAR MEDICINE; RATS; SURFACE ACTIVE AGENTS; TUMORS;

BRAIN;

DENDRIMER; DOCETAXEL; NANOCONJUGATE; POLYPROPYLENE; POLYSORBATE 80;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SIZE; CANCER SURVIVAL; CONJUGATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG RELEASE; GAMMA SCINTIGRAPHY; GLIOBLASTOMA; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; RAT; SURVIVAL TIME; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DENDRIMERS; GLIOBLASTOMA; HUMANS; MALE; NANOCONJUGATES; POLYSORBATES; RATS; SURFACE-ACTIVE AGENTS; TAXOIDS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

ANIMALIA; RATTUS;

EID: 79959861668     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.04.057     Document Type: Article

References (29)

1. Huynh G.H., Deen D.F., Szoka F.C. Barriers to carrier mediated drug and gene delivery to brain tumors. J Control Rel 2006, 110:236-259.
2. Armstrong T.S., Mendoza T., Gring I., Coco C., Cohen M.Z., Erriksen L., et al. Anderson symptom inventory brain tumor module (MDASI-BT). Neuro Oncol 2006, 80:27-35.
3. Behin A., Hoang-Xuan K., Carpentier A.F., Delattre J.Y. Primary brain tumours in adults. Lancet 2003, 361:323-331.
4. Winer E., Gralow J., Diller L., Karlan B., Loehrer P., Pierce L., et al. Clinical cancer advances 2007: major research advances in cancer treatment, prevention and, screening- a report from the American society of clinical oncology. J Clin Oncol 2009, 27:812-826.
5. Eyal S., Hsiao P., Unadkat J.D. Drug interactions at blood-brain barrier: fact or fantasy?. Pharmacol Therapeut 2009, 123:80-104.
6. Beduneau A., Saulnier P., Benoit J.P. Active targeting of brain tumors using nanocarriers. Biomaterials 2007, 28:4947-4967.
7. Ying X., Wen H., Lu W., Du J., Guo J., Tian W., et al. Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals. J Control Rel 2010, 141:183-192.
8. Carroll R., Bhatia D., Geldenhuys W., Bhatia R., Miladore N., Bishayee A., et al. Brain-targeted delivery of Tempol-loaded nanoparticles for neurological disorders. J Drug Target 2010, 18:665-674.
9. Wu G., Barth R.F., Yang W., Kawabata S., Zhang L., Green-Church K. Targeted delivery of methotrexate to epidermal growth factor receptor-positive brain tumors by means of cetuximab (IMC-C225) dendrimer bioconjugates. Mol Cancer Ther 2006, 5:52-59.
10. Ren Y., Kang C.S., Yuan X.B., Zhou X., Xu P., Han L., et al. Co-delivery of as-miR-21 and 5-FU by poly(amidoamine) dendrimer attenuates human glioma cell growth in vitro. J Biomater Sci Polym Ed 2010, 21:303-314.
11. Gajbhiye V., Kumar P.V., Tekade R.K., Jain N.K. Pharmaceutical and biomedical potential of PEGylated dendrimers. Curr Pharm Design 2007, 13:415-429.
12. Patri A.K. Targeted drug delivery with dendrimers: comparison of the release kinetics of covalently conjugated drug and non-covalent drug inclusion complex. Adv Drug Del Rev 2005, 57:2203-2214.
13. Dutta T., Agashe H.B., Kumar P.V., Garg M., Jain N.K. Dendrosome-based gene delivery. J Exp Nanosci 2006, 1:235-248.
14. Gupta U., Agashe H.B., Jain N.K. Polypropylene imine dendrimer mediated solubility enhancement: effect of pH and functional groups of hydrophobes. J Pharm Pharmaceu Sci 2007, 10:358-367.
15. Kobayashi H., Brechbiel M.W. Nano-sized MRI contrast agents with dendrimer cores. Adv Drug Deliv Rev 2005, 57:2271-2286.
16. Gajbhiye V., Kumar P.V., Tekade R.K., Jain N.K. Dendrimers as therapeutic agents: a systematic review. J Pharm Pharmacol 2009, 61:989-1003.
17. Tekade R.K., Kumar P.V., Jain N.K. Dendrimers in oncology: an expanding horizon. Chem Rev 2009, 109:49-87.
18. Dutta T., Jain N.K. Targeting potential and anti-HIV activity of lamivudine loaded mannosylated poly (propyleneimine) dendrimer. Biochim Biophys Acta 2007, 1770:681-686.
19. Blasi P., Giovagnoli S., Schoubben A., Ricci M., Rossi C. Solid lipid nanoparticles for targeted brain drug delivery. Adv Drug Del Rev 2007, 59:454-477.
20. Gajbhiye V., Kumar P.V., Sharma A., Jain N.K. PEGylated PPI dendritic architectures for sustained delivery of anti-inflammatory agent. Curr Nanosci 2008, 4:267-277.
21. Gajbhiye V., Kumar P.V., Tekade R.K., Jain N.K. Novel PEGylated nanoparticulate architectures for sustained delivery of H2 receptor antagonist. Euro J Med Chem 2009, 44:155-166.
22. Beban M., Miller P.S. Preparation of an imidazole-conjugated oligonucleotide. Bioconjug Chem 2000, 11:599-603.
23. Agashe H.B., Babbar A.K., Jain S., Sharma R.K., Mishra A.K., Asthana A., et al. Investigation on biodistribution of technetium-99m-labeled carbohydrate-caoted poly(propylene imine) dendrimers. Nanomedicine: NBM 2007, 3:120-127.
24. Fujita M., Lee B.S., Khazenzon N.M., Penichet M.L., Wowrowsky K.A., Patil R., et al. Brain tumor tendem targeting using a combination of monoclonal antibodies attached to biopoly(β-L-malic acid). J Control Rel 2007, 122:356-363.
25. Zhao L., Wei Y., Zhong X., Liang Y., Zhang X., Li W., et al. PK and tissue distribution of docetaxel in rabitts after i.v. administration of liposomal and injectable formulations. J Pharm Biomed Anal 2009, 49:989-996.
26. Gupta U., Dwivedi S.K.D., Bid H.K., Konwar R., Jain N.K. Ligand anchored dendrimers based nanoconstructs for effective targeting to cancer cells. Int J Pharm 2010, 393:185-196.
27. Rowe J.D.D., Bello J., Mitnick R., Sood B., Filippi C., Moran J., et al. Accelerated regression of brain metastases in patients receiving whole brain radiation and the topoisomerase II inhibitor, lucanthone. Int J Radia Onco Biol Phys 1999, 43:89-93.
28. Kemper E.M., Verheij M., Boogerd W., Beijnen J.H., van Tellingen O. Improved penetration of docetaxel into brain by co-administration of inhibitors of P-glycoprotein. Euro J Cancer 2004, 40:1269-1274.
29. Kreuter J., Shamenkov D., Petrov V., Ramge P., Cychutek K., Koch-brandt C., et al. Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier. J Drug Target 2002, 10:317-325.